Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 143

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 143
---
.68; p = 0.066) and PFS was 3.48 months for fruquintinib versus 1.84 months for placebo (hazard ratio = 0.24; p < 0.001).

Additional data showed that there were no observed cumulative CTC grade 3 or above TEAEs in the subgroup of patients with prior target therapy. The CTC grade 3 or above TEAEs rates of fruquintinib were similar in the subgroups with prior target therapy (61.3%) and without prior target therapy (61.1%). This subgroup analysis is consistent with the previously reported results from the FRESCO study’s intent-to-treat population. The results of this analysis showed that fruquintinib had clinically meaningful benefits in 3L CRC patients regardless of prior target therapy without observed cumulative toxicity.

Table of Contents

Quality-adjusted survival analysis

At ASCO 2018, an analysis was presented that aimed to compare the quality-adjusted survival between the two arms of the FRESCO study using quality-adjusted time without symptoms or toxicity (“ Q-TWiST”) methodology. Patients treated with fruquintinib had longer Q-TWiST periods compared to patients treated with placebo. Q-TWiST benefits were observed regardless of prior lines of chemotherapy and prior anti-VEGF or anti-EGFR targeted therapy. The relative improvement of Q-TWiST with fruquintinib represents a clinically important quality-of-life benefit for mCRC patients.

Fruquintinib in Combination with Checkpoint Inhibitors

In November 2018, we entered into a global collaboration with Innovent to evaluate the combination of fruquintinib with Innovent’ s Tyvyt, a PD-1 monoclonal antibody approved in China.

  Treatment                 Trial Name, Patient Focus                                            Sites      Phase       Status/Plan                                                                          NCT #        
  Fruquintinib + Tyvyt      FRUSICA-3: 2L pMMR EMC                                               China      III         Started Dec 2024                                                                     NCT06584032  
  Fruquintinib + Tyvyt      FRUSICA-1: 2L pMMR EMC                                               China      II          Approved and launched in China                                                       NCT03903705  
  Fruquintinib + Tyvyt      Dose escalation: CRC, BTC, colon cancer, head & neck and others      China